[The @entity7555 with coexisting XXXX --case report].

@entity1 @entity1375 @entity10805 @entity1581 @entity7 @entity4 @entity229 @entity2816 @entity305 @entity79 @entity2744 @entity7555 @entity6126 @entity4903 @entity288
We present a case of a @entity1 with unique multisystem @entity7555 and @entity4903 coexisting with it. The POEMS acronym comprises the dominant features: @entity305 , @entity7555 , @entity2744 , monoclonal protein ( @entity10805 ), skin changes. Association between @entity1581 and @entity305 , was described in 1956 year by Crow. The main features were coined in the acronym POEMS by Bardwick in 1980 year. The polysymptomatic clinical picture, progressive course and no-concurrent manifestations of main features impede the diagnosis. In this case, the first symptoms were the sensomotor @entity305 , @entity4 , @entity79 , skin changes, @entity7555 . They preceded diagnosis by 3 years. The first @entity2744 was @entity1375 . Definite diagnosis was delayed because we couldn't detect the presence of @entity10805 . Immunoelectrophoresis didn't detect it, but analysis by immunofixation detected @entity10805 in serum and urine. Within 3 years of the first symptoms, she developed @entity6126 hypergonadotropic. At first, the monotherapy with @entity288 was used, then--melfalan with @entity229 . Due to the progression of the disease, a @entity2816 was used in therapy (it is anti- @entity7 agent). One of the side effects of the treatment of @entity2816 is the progression of @entity305 , which was observed in this @entity1 . After finishing this therapy she received chemotherapy. This case report imposes the necessity of constants observation of @entity1 with @entity7555 because there is a possibility of their developing other disorders. In the event of coexistence @entity305 and @entity1581 , this disease should be taken into consideration.
